Australian radiopharmaceutical company Cyclopharm (ASX:CYC) has achieved a significant milestone in its US expansion, with Lucile Packard Children’s Hospital Stanford set to implement Technegas for paediatric lung imaging.
The agreement marks the first time a dedicated children’s hospital in the United States has adopted Technegas, an important step in Cyclopharm’s strategy to broaden access to its technology across leading clinical centres. While Stanford Medicine was among the earliest major US institutions to introduce Technegas for adult patients, extending its use into paediatric care reflects growing confidence in the product’s safety, utility and clinical value.
Technegas is widely recognised for its established safety profile, ease of use and low radiation dose, attributes that are particularly critical in paediatric medicine, where minimising radiation exposure is paramount. Its ability to deliver high-quality functional lung ventilation imaging has traditionally supported the diagnosis of pulmonary embolism, but its clinical applications have continued to expand into conditions such as asthma, chronic obstructive pulmonary disease, pulmonary hypertension and interventional planning.
The adoption by Lucile Packard Children’s Hospital Stanford represents a meaningful endorsement of Technegas’ suitability for younger patients, where compliance, imaging quality and safety must align seamlessly. For clinicians, the technology offers a non-invasive and effective way to visualise lung function in children who may otherwise struggle with traditional imaging modalities.
Cyclopharm Managing Director James McBrayer said the company was delighted to see Technegas introduced into the paediatric setting at one of the most respected children’s hospitals in the US. He noted that the company looks forward to supporting Stanford Medicine Children’s Health as Technegas is integrated into clinical practice, building on the success already seen in adult care.
The Stanford agreement comes as Cyclopharm continues to progress a growing number of installations across leading academic and clinical centres nationwide. Each new site strengthens the company’s US footprint and supports its broader mission to equip nuclear medicine and respiratory clinicians with tools that improve diagnostic accuracy and patient outcomes.
As Technegas gains traction beyond its original indications and into new patient populations, the Stanford milestone underscores Cyclopharm’s momentum in the world’s largest healthcare market and its ability to translate proven technology into meaningful advances in patient care.